Unknown NA INTERVENTIONAL 2-arm NCT04400786

A Randomized Open-labeled Study for Comparing Methods of Using Imrecoxib to Treat AS

A Randomized Open-labeled Study for Comparison of Patient-reported Outcomes Between Two Therapeutic Schedules of Imrecoxib in Ankylosing Spondylitis

Sponsor: Shanghai Zhongshan Hospital

Conditions Ankylosing Spondylitis Therapeutic Agent Toxicity

Interventions continuous treatment intermittent treatment

Updated 5 times since 2020 Last updated: May 22, 2020 Started: May 7, 2020 Primary completion: Dec 31, 2021 Completion: Jun 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04400786, this NA trial focuses on Ankylosing Spondylitis and Therapeutic Agent Toxicity and remains ongoing. Sponsored by Shanghai Zhongshan Hospital, it has been updated 5 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Sep 2022 — Jul 2024 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Jan 2021 — Sep 2022 [monthly]

Recruiting NA
Jun 2020 — Jan 2021 [monthly]

Recruiting NA

First recorded

May 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Zhongshan Hospital
Wu Jieping Medical Foundation

Data source: Shanghai Zhongshan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China